STAT

A daredevil researcher’s latest quest: to restore sight lost to glaucoma using virtual reality

This Stanford neuroscientist is testing an intriguing but unproven hypothesis: that virtual reality could be used to preserve or even restore vision for patients with glaucoma.

PALO ALTO, Calif. — In the name of science, Andrew Huberman has gone diving 40 feet underwater with great white sharks. He’s gone mountain climbing without ropes or harnesses, traversing some sections where one slip would have sent him plummeting 650 feet.

Now, the Stanford neuroscientist is embarking on a different kind of daring quest, testing an intriguing but unproven hypothesis: that virtual reality could be used to preserve or even restore vision for patients with glaucoma.

Academics and companies all over the world are betting on virtual reality to help patients with conditions like anxiety, depression, PTSD, and ADHD. Huberman believes in the potential of the technology for vision issues, too, but he speaks about it less like an evangelist than someone who’s discovered a useful tool. He’s also harnessing it in pioneering ways.

In the case of his glaucoma clinical trial, Huberman is asking patients to gaze at flashing white dots in the hopes that they can trigger the firing of neurons that connect the eye to the brain and coax them to regenerate.

He’s also using virtual reality to study the physiology of anxiety and fear. He has recruited volunteers to watch virtual reality footage of scenarios they may never encounter in real life: Being attacked by a dog. Climbing more than 250 feet up a tree. And swimming with sharks.

Huberman, 42, traveled to many of the shoots, putting himself in personal danger to collect the footage

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related Books & Audiobooks